Compare KRUS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | EOLS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.2M | 529.1M |
| IPO Year | 2019 | 2018 |
| Metric | KRUS | EOLS |
|---|---|---|
| Price | $41.39 | $7.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $67.00 | $15.00 |
| AVG Volume (30 Days) | 211.5K | ★ 613.8K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | 1.23 |
| EPS | N/A | ★ N/A |
| Revenue | $282,763,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $16.97 | $12.44 |
| Revenue Next Year | $18.28 | $17.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | 11.61 |
| 52 Week Low | $33.97 | $3.86 |
| 52 Week High | $80.84 | $9.31 |
| Indicator | KRUS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 45.13 |
| Support Level | $33.97 | $7.59 |
| Resistance Level | $59.30 | $8.47 |
| Average True Range (ATR) | 1.90 | 0.29 |
| MACD | 0.71 | -0.06 |
| Stochastic Oscillator | 83.51 | 29.89 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.